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ABSTRACT 
Background: The objective of this study is to explore the use of bcr-abl Tyrosine 
Kinase Inhibitors in the treatment of chronic myeloid leukemia (CML) patients at the 
CMJAH Medical Oncology Unit in Johannesburg, South Africa, and to confirm the 
evidence from bodies such as the European LeukaemiaNet (ELN) that the era of bcr-
abl TKIs has significantly advanced the treatment of CML,  with affected patients living 
normal lives in their chronic phase, therefore making allogeneic stem cell 
transplantation no longer an essential part of therapy. 
Method: A cohort of 101 adult patients diagnosed with CML, 48% males and 52% 
females, with a median age of 40 years, were retrospectively analysed using data 
from their clinic files. The Sokal score could be evaluated as a pretreatment prognostic 
tool in 55% of the patients. Molecular responses to three sequential TKIs ie. Imatinib 
followed by dasatinib and nilotinib, were sought by the monitoring of serial RQ-PCRs. 
Adverse effects and mutational analyses were also analysed.  
Results: Once patients were started on bcr-abl TKI therapy (post the interferon-α 
era), better treatment responses were seen and better overall survival achieved 
without progression to advanced stages of CML. In addition, second line TKI therapy 
showed a benefit following the first line TKI imatinib. TKIs were generally well tolerated 
with 63 of the 101 patients experiencing grade 3/ 4 AEs mainly due to haematological 
toxicity. A low number of documented mutations (3 out of 101) also suggest that TKI 
therapy is very effective in treating CML. 
Conclusion: There seems to be an improved outcome with TKI therapy compared to 
the older interferon alpha based therapy; as well as a treatment response with second 
generation TKI therapy in patients at the CMJAH Medical Oncology unit treated for 
CML. Patients on TKI therapy remained in CP-1 of CML for longer periods without 
transformation to advanced stages of CML, with improved PFS and 5 year OS, as 
long as they were compliant on treatment. Hematological adverse effects were 
observed due to both dasatinib and imatinib therapy.  
 
Key words: Chronic myeloid leukaemia; Tyrosine kinase inhibitor; Molecular 
response; Overall survival; Progression free survival. 
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Chapter 1 
 Background, Rationale and Motivation for this Study 
1. Introduction 
1.1 Chronic Myeloid leukaemia (CML) 
Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disorder which accounts 
for 15 to 20 percent of all adult leukaemias (Walz et al., 2008). The median age of 
occurrence is about 50 years for patients enrolled in clinical studies with an incidence of 2 
per 100, 000/year with a slight male predominance (Louw et al., 2012); (Walz et al., 
2008). South African leukaemia incidence data from the South African National Cancer 
Registry, for 2011 reported a leukaemia incidence with a total of 750 new cases of 
leukaemia (437 male, ASR 2.33 per 100,000 population and 313 female, ASR 1.33 per 
100,000) reported, with no specific classification of the type of leukaemia mentioned 
(Singh et al., 2013). With the increased use and availability of bcr-abl tyrosine kinase 
inhibitors, the incidence of CML is steadily increasing worldwide due to more patients 
surviving and living longer (Louw et al., 2012); (Walz et al., 2008). It is important to note 
that although CML can occur in any age group; this research will focus on the adult 
population (>18 years of age). 
CML is characterized by a clonal expansion of the haematopoietic stem cells associated 
with a translocation between the long arms of chromosomes 9 and 22 {t(9;22)} which 
results to the formation of the Philadelphia chromosome (Ph) (Louw et al., 2012); (Wetzler 
M et al., 2008). The t(9;22) translocation results in fusion of the breakpoint cluster region 
(BCR) gene on chromosome 22 at band q11 with the Abelson murine leukaemia (ABL) 
gene  located on chromosome 9 at band q34 (O'Brien et al., 2003); (Wetzler M et al., 
2008). This results in the BCR-ABL fusion gene which codes for a 210 kilodalton fusion 
protein, p210, which plays a central role in the initial development of CML with has 
deregulated tyrosine kinase activity. The p190 BCR-ABL fusion protein is usually 
associated with Ph+ acute lymphoblastic leukaemia (ALL). (O'Brien et al., 2003).  
Pathogenesis of CML involves p210 being constitutively activated leading to increased 
proliferation of myeloid cells, enhanced cell adhesion, decreased apoptosis and genetic 
instability of the leukaemic cells. It is this genetic instability that forms the basis for  
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resistance to treatment and progression of disease to an acute leukaemic or blastic phase 
(Louw et al., 2012); (Wetzler M et al., 2008). 
CML is characterised by the uncontrolled production of mature and maturing granulocytes 
which are predominantly of the neutrophil series, but can also have increased basophils 
and eosinophils (Walz et al., 2008). CML has a triphasic clinical course namely a chronic 
phase (CP-CML), which is present at the time of diagnosis in approximately 85% of  
patients followed by an advanced phase, which includes the accelerated phase (AP-CML) 
and the blast crisis (BC-CML) (Walz et al., 2008). (See Table 1.1). 
Table 1.1: Definition of phases of CML (Baccarani et al., 2013); (Louw et al., 2012). 
ELN criteria                                                      WHO criteria 
Chronic phase (CP) 
None of the criteria for AP or BP met                    
Accelerated phase (AP) 
Blast cells in PB or BM 15-29%,         Blasts in PB or BM 10-19% 
Blasts + promyelocytes in PB or                   Basophils in PB ≥ 20% 
BM> 30%, with blasts < 30%         Persistent thrombocytopenia  
Basophils in PB ≥ 20%          (<100 x 109/L) unrelated to  
Persistent thrombocytopenia         therapy 
Unrelated to therapy          CCA/Ph+ on treatment 
Clonal chromosome abnormalities        Thrombocytosis (>1000 x 109/L) 
in Ph+ cells (CCA/Ph), major route,                unresponsive to therapy 
on treatment             Increasing spleen size and  
            Increasing WBC count 
            Unresponsive to therapy 
Blast phase (BP) 
Blasts in PB or BM ≥30%          Blasts in PB or BM ≥20% 
Extramedullary blast proliferation,         extramedullary blast proliferation, 
apart from spleen           apart from spleen 
            Large foci or clusters of blasts in 
            BM biopsy 
PB= peripheral blood; BM= bone marrow 
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If untreated early in the course of the disease or if drug resistance occurs, CML will 
progress to an advanced phase within 3-5 years.(O’Brien et al., 2014) In the accelerated 
phase neutrophil differentiation becomes progressively impaired and leukocyte count 
more difficult to control with treatment associated with an increase in basophils and a 
decrease in platelets. The blast crisis resembles an acute leukaemia and can either have 
myeloid (75%) or lymphoid (25%) blasts proliferating in an uncontrolled manner (Etten et 
al., 2016).  
Patients are usually asymptomatic at diagnosis with an incidental finding of a raised white 
blood cell count (WBC) on peripheral blood. Symptoms include fatigue, malaise, weight 
loss, left sided abdominal fullness and early satiety (secondary to splenomegaly), and 
less commonly bleeding due to platelet dysfunction (Louw et al., 2012). Clinically 
splenomegaly is the most common finding, there may also be hepatomegaly, gouty 
arthritis, pallor, features of hyperviscosity related to high WBC count (e.g. headache, 
visual and hearing disturbances, angina, dyspnoea, bone pain and priapism) (Louw et al., 
2012). Commonly in the blast phase of the disease there may be extramedullary 
involvement beyond the spleen including lymph nodes, skin, soft tissue and liver, which 
may have prognostic and staging implications (Etten et al., 2016). 
The work-up of CML therefore entails a good history and physical examination. The 
following laboratory tests are required to confirm the diagnosis: 
 A full blood count with a peripheral smear demonstrates a leukocytosis with a median 
WBC of approximately 100,000/µl (normal range 12 to 100/µl), but may exceed 
1,000,000/µl (Etten et al., 2016). The WBC differential count typically shows virtually all 
cells of the neutrophil differentiation, from myeloblasts to mature neutrophils with a peak 
in the percentage of myelocytes and segmented neutrophils (Etten et al., 2016).  A 
“myelocytic bulge” which is the presence of a greater percent of myelocytes than mature 
metamyelocytes is one of the classic findings in CML. Absolute basophilia is universally 
found in the blood smear of CML patients with absolute eosinophilia also seen in 90% of 
cases. A normocytic anaemia is seen in 45 to 60 percent of patients with the platelet 
count can either normal or, in most cases elevated (Etten et al., 2016).  
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Bone marrow aspirate and trephine biopsy shows a granulocyte hyperplasia with a 
maturation pattern similar to that seen on peripheral blood smear. Both bone marrow 
aspirate and peripheral blood smear are key components in determining disease stage 
(Etten et al., 2016). Testing for Ph chromosome is demonstrated by conventional 
cytogenetic analysis (karyotyping), while BCR-ABL1 fusion gene is demonstrated by 
fluorescence-in-situ-hybridization (FISH) analysis or by real-time quantitative polymerase 
chain reaction (RQ-PCR) (Etten et al., 2016). All patients with CML have evidence of 
either the Ph+ chromosome, the BCR-ABL1 fusion gene or its product the BCR-ABL1 
fusion mRNA (Etten et al., 2016). 
Three prognostic systems:  Sokal, Euro (Hasford), and EUTOS (European Treatment and 
Outcome Study Score); based on simple clinical and haematological data, have been 
shown to be of prognostic value in treatment naïve CP-CML. (Baccarani et al., 2013); 
(Etten et al., 2016).                                                                
For the Sokal score to be calculated, the following variables are required: age, spleen 
size in centimetres, platelet count and blast count. (See Table 1.2)                             
 For the Hasford score to be calculated variables needed are age, spleen size, blast 
count, basophil count and eosinophil count. (See Table 1.2).    
The latest (2013) guidelines for CML management by the European LeukaemiaNet (ELN) 
suggest the use of risk stratification systems to influence overall clinical 
outcome.(Baccarani et al., 2013). 
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Table 1.2: Prognostic scores in CML (Etten et al., 2016); [7];(Hasford et al., 1998); 
(Hasford et al., 2011); (Sokal et al., 1984). 
Study Calculation  Risk calculation  by definition 
Sokal et al. 
19846 
Exp 0.0116 x (age - 43.4)  + 0.0345 x 
(spleen – 7.51) + 0.188 x[(platelet count ÷ 
700)2  –  0.563] + 0.0887 x (blast cells – 
210)                         
Low risk: < 0.8  
Intermediate risk: 0.8 - 1.2  
High risk: >1.2 
 
Euro 
Hashford et 
al. 19987           
 
0.666 when age ≥ 50y + (0.042 x spleen) 
+ 1.0956 when  platelet count > 1500 x 
109L + (0.0584 X blast cells ) + 0. .20399 
when basophils > 3% + (0.0413 x 
oesinophils) x 100                                                                                    
 
Low risk: ≤ 780  
Intermediate risk: 781-1480 
 High risk: > 1480 
 
EUTOS 
Hashford et 
al. 20118                                                                                                                                                 
 
Spleen x 4 + basophils x 7                        
                                                                  
 
Low risk: ≤ 87   
High risk: > 87                    
Note: Spleen size in centimetres 
 
Before the era of BCR-ABL TKIs, the treatment of CML included busulphan, hydroxyurea, 
interferon-α ± low dose cytarabine , and allogeneic haematopoietic stem cell 
transplantation (Louw et al., 2012). Since the introduction of BCR-ABL1 TKIs, which 
specifically target the non-receptor tyrosine kinase activity of the oncogenic protein 
encoded by BCR-ABL fusion gene, the management and outcome of CML has 
significantly improved (Louw et al., 2012). The first-generation BCR-ABL1 TKI, imatinib 
was the first to be approved by the US FDA (United States Food and Drug Administration) 
and South African MCC (Medicines Control Council) as first-line therapy for patients with 
CML after the IRIS study showed that after a median of 19 months, imatinib was 
significantly better than interferon-α ± cytarabine based treatment, as shown by the rates 
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of complete haematological response (CHR) of (95% vs 56%), and  MCyR (≤ 35% Ph+ 
cells in metaphase); 85% vs 22%, and CCyR of 68% versus 8%. MMR rates at 12 months 
of (40% vs 2%) and CML Progression Free Survival (PFS) was also shown to be superior 
with imatinib (Baccarani et al., 2013); (O'Brien et al., 2003). 
1.2 BCR-ABL1 Tyrosine Kinase Inhibitors (TKIs) 
Tyrosine Kinases are enzymes responsible for the phosphorylation of tyrosine amino-
acids resulting in the activation of various proteins involved in signal transduction 
cascades. The activation of these proteins is by the addition of a phosphate group to 
tyrosine amino-acids in the tyrosine kinase residue protein, ie. phosphorylation (Schiffer, 
2007). BCR-ABL TKIs block the initiation of the BCR-ABL1 pathway by blocking its ATP 
binding site and thereby inhibiting phosphorylation and preventing a conformational 
switch to the active form, inhibiting signal transduction and thereby cellular proliferation 
and tumour formation without inducing apoptosis, thus producing a 92-98% decrease in 
CML growth in vitro without inhibiting normal cellular growth (Schiffer, 2007); (Jabbour et 
al., 2007).                                                                                                   
It should be noted that BCR-ABL TKIs may also block other signalling pathways, making 
them effective in other haematological as well as solid tumours, e.g. imatinib also inhibits 
mutant platelet-derived growth factor α and β (PDGFR-α and β) and c-Kit (CD117, Stem 
Cell Factor Receptor) in Gastrointestinal Stromal Tumours (GISTs); (Giles et al., 2009); 
(Schiffer, 2007).                                                                              
In CML however, imatinib is shown to specifically inhibit proliferating myeloid cell lines 
containing the BCR-ABL1 fusion gene without affecting or destroying normal cells of the 
granulocyte series. (Jabbour et al., 2007). 
1.3 Response to BCR-ABL1 TKIs 
Therapeutic responses are usually assessed with standardized real-time quantitative 
polymerase chain reaction (RQ-PCR) and/or cytogenetics (See Table 1.3); With 3, 6, 12, 
and 18 month intervals used as indicators of adequate response to treatment (Baccarani 
et al., 2013). With regards to RQ-PCR, a BCR-ABL1 transcription of <10% (1 log 
reduction) at 3 months, <1% (2 log reduction) at 6 months, and <0.1% (3 log reduction) at 
12 months onwards defines an optimal response (Baccarani et al., 2013). Whereas a 
>10% BCR-ABL1 at 6 months and >1% at 12 months and onwards defines treatment 
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failure, requiring consideration of a change to second-line treatment. In the same token, 
with regards to cytogenetic response, partial cytogenetic response (PCyR) (<35% Ph+) at 
3 months and complete cytogenetic response (CCyR) from 6 months onwards defines 
optimal treatment response. Failure is defined by a Ph+ chromosome of >95% at 3 
months, less than PCyR at 6 months, and less than CCyR from 12 months onwards. 
Important to note is that treatment failure is confirmed when two or more samples show 
an increase in BCR-ABL transcripts  (Baccarani et al., 2013);  (Louw et al., 2012). 
1.4 Adverse effect of BCR-ABL1 TKIs 
The development of BCR-ABL1 tyrosine kinase inhibitors for the treatment of CML over 
the past twenty years has increasingly improved outcomes and management of chronic 
myeloid leukaemia (Larson, 2015). Worldwide oncologists and haematologists have 
access to 5 oral agents for treating CML. Three of these are available in South Africa; 
namely imatinib, nilotinib and dasatinib which are all approved as first line therapy and are 
generally well tolerated and very effective in CML management. (Larson, 2015). With 
current practice it seems that patients with CML are remaining on BCR-ABL TKIs therapy 
indefinitely, therefore clinicians need to familiarise themselves with the early and late 
toxicities associated with BCR-ABL TKI use (Larson, 2015). Efficacy is important; so 
choosing the appropriate medicine will be guided by understanding each agent with 
regards to its benefits and risks and patient-specific factors such as risk status, age, and 
comorbidities. (Larson, 2015). 
Adverse effects (AEs) of BCR-ABL TKI therapy are rarely severe (grade 3/ 4). It is 
therefore important to recognise and treat these toxicities early as low grade toxicities 
may over a long period of time impact on compliance and eventually on overall survival 
(Giles et al., 2009); (Larson, 2015).  
There seems to be a relationship between kinase inhibitor mechanism of action of BCR-
ABL TKI therapy and safety profile(Giles et al., 2009).  
i. Inhibition of ABL kinase. ABL is a key mediator of normal cardiac function 
and is expressed in cardiac cells. There is therefore an increased incidence 
of cardiac adverse events on second generation BCR-ABL1 TKI, dasatinib 
and nilotinib compared to imatinib. These cardiac AEs include QT 
prolongation, arrhythmias, left ventricular dysfunction and rarely present as 
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grade 3/4 AEs. They also more commonly occur with dasatinib use than 
with nilotinib (Giles et al., 2009). 
ii. SRC kinase inhibition. SRC is important in signalling for normal 
haematopoiesis. SRC family members HCK, LYN, FGR, LCK, and, BLK are 
expressed only in haematopoeitic cells. With HCK critical in development 
and survival of myeloid and B lymphocytes. LYN is an important modulator 
of erythropoiesis, modulating erythroid progenitor cell expansion to promote 
erythroid survival. Out of the three BCR-ABL TKIs, dasatinib strongly inhibits 
SRC kinases with myelosuppression more common on patients being 
treated with dasatinib than with the other two BCR-ABL TKIs (Giles et al., 
2009). 
iii. Platelet- derived growth factor receptor (PDGFR) affects fluid retention and 
serosal inflammation. PDGFR is expressed in pericytes and lung tissue, and 
is also involved in angiogenesis regulation. Its inhibition therefore causes 
changes in interstitial pressures and fluid haemostasis in vascular 
compartments and extracellular compartments. This results in the 
development of oedema and third spacing of fluids. Other factors also 
influence pleural and pulmonary parenchymal fluid retention, this occurs 
when SRC inhibition affect vascular permeability (Giles et al., 2009). 
iv. C-kit receptor is normally expressed in skin, basal cells, melanocytes, 
epithelial cells of the breast, mast cells and intestinal pacemaker cells of 
Cajal. Imatinib  inhibits C-kit, causing patients  to develop rashes and other 
cutaneous reactions (Giles et al., 2009). 
C-kit is also important in the development of normal blood cells. It therefore 
explains why some patients on imatinib and less so on nilotinib develop 
cytopenias due to myelosuppressive effects of therapy(Giles et al., 2009).  
 
 
 
9 
 
Overall imatinib is well tolerated and effective in treatment of CP-CML. The common 
documented non- haematological AEs on imatinib are rashes, fatigue, headache, nausea, 
diarrhoea, muscle pains as well as haematological AEs  reported above, especially 
myelosuppression (Giles et al., 2009). 
Dasatinib was initially developed as a SRC inhibitor and subsequently found to be a 
powerful BCR-ABL1 inhibitor with 300 times the potency of imatinib in-vitro. While nilotinib 
was developed as an analogue of imatinib, with 30 times the potency of imatinib in-vitro 
(Kantarjian et al., 2010); (Saglio et al., 2010). 
Nilotinib and dasatinib are both highly active in treating those CML patients who have 
failed imatinib because of resistance or intolerance (Giles et al., 2009). Common non- 
haematological AEs of nilotinib although not usually clinically significant are arrhythmias 
due to QTc prolongation, elevations in bilirubin and lipase levels, pancreatitis and 
hyperglycaemia, which rarely require directed therapy (Giles et al., 2009). The non- 
haematological AEs for dasatinib are headache, fluid retention including pleural effusion, 
pulmonary arterial hypertension, QTc interval prolongation and other cardiac events. 
(Giles et al., 2009).     
Data on both safety and efficacy is now available for imatinib after 10 years for initial 
therapy and 5-6 years for dasatinib and nilotinib therapy. (Larson, 2015).  
1.5 Monitoring in CML  
1.5.1 Cytogenetics 
Conventional cytogenetics have been the gold standard for decades, since the 
description of the Ph chromosome by Nowell and Hungerford in 1961, in the diagnosis 
and monitoring in CML. Cytogenetic responses are defined in terms of the percentage of 
cells that are in metaphase existing within the bone marrow that are Ph chromosome 
positive. This response is based upon a usual sample size of twenty cells in metaphase 
(Hughes et al., 2003); (Hughes et al., 2006). There are limitations to karyotyping as there 
is a high rate of failure due to lack of metaphase especially in patients with low WBC 
counts. In addition high costs, delayed results and invasive bone marrow procedures limit 
this procedure. Reference ranges for cytogenetic response are complete cytogenetic 
response (CCyR)- (no Ph+ metaphases - 0%), partial cytogenetic response (PCyR) – (1- 
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35% Ph+ metaphases), major cytogenetic response (complete and partial) – (0- 35% Ph+ 
metaphases), minor response- (>35% but <90% Ph+ metaphases). (See Table 1.3) 
(Baccarani et al., 2013); (Hughes et al., 2006).  
1.5.2 Fluorescence-in-situ-hybridization (FISH) 
FISH is done on peripheral blood (BP) or bone marrow looking at approximately 200 
interphase cells with BCR-ABL1 translocation in myeloid cells. It may be less invasive, 
faster and less costly to carry out (Hughes et al., 2006). However it is an inferior method 
of quantifying and thereby monitoring disease response on both interferon-α therapy and 
BCR-ABL1 TKI therapy, being only semi-quantitative. It is therefore only useful for 
diagnosing CML, as an alternative measure when conventional cytogenetics are 
unavailable or inadequate (Hughes et al., 2006).  
1.5.3 Molecular (RQ-PCR) 
Molecular response in CML is measured using the percentage of  BCR-ABL1 fusion 
transcripts (Hughes et al., 2003). This transcript is a marker of the presence and amount 
of transcriptionally active Ph chromosome positive leukaemia cells in CML patients. 
mRNA is extracted and purified from leukocytes, then reverse transcribed (RT) and the 
cDNA product is then quantified by fluorescent real-time quantitative polymerase chain 
reaction (RQ-PCR) (Branford et al., 2008); (Hughes et al., 2003); (Hughes et al., 2006).  
The RQ-PCR test must also analyse an endogenous control transcript (EC), usually either 
ABL or GUS to assess the quality and quantity of RNA and to normalize the potential 
differences between tests (Hughes et al., 2003); (Branford et al., 2008). Therefore 
monitoring of response to BCR-ABL1 TKI therapy is based on a variation of BCR-ABL1 
expression levels over time, measured in fold change or more commonly log reduction 
change. RQ-PCR reference ranges are MMR3 (log 3 reduction)- ≤ 0.1%, MR4 (log 4 
reduction)- < 0.01%, MR4,5 (log 4,5% reduction)- < 0.0032%), and MR5 (log 5 reduction)- 
< 0.001%. (Baccarani et al., 2013). (See Table 1.3).   
1.5.4   International Scale (IS) 
The International Scale (IS) was established in 2005 to standardize quantitative BCR-
ABL1 measurements across tests and laboratories (Branford et al., 2008). The (IS) is 
anchored to the baseline BCR-ABL1 expression level from the International Randomized 
Study of Interferon vs STI571 (IRIS) Trial (100% IS) with a major molecular response 
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(MMR) corresponding to 0.1% IS. (Branford et al., 2008). The IRIS Trial and follow-up 
studies have demonstrated that achieving MMR3, or 3-log reduction in BCR-ABL1 
expression from standardized baseline level is a key outcome in the treatment of CML. 
(Branford et al., 2008). ELN recommendations state that it is not possible to assess 
achievement of MMR3 if  the (IS) is not available (Baccarani et al., 2013). The importance 
of the (IS) is that it standardises quantitative BCR-ABL1 measurements across test 
laboratories, facilitating inter-laboratory studies, patient portability, and harmonized 
definition of treatment response across the board (Hughes et al., 2003); (Branford et al., 
2008). This scale was consolidated at the consensus meeting on October 2005 at the NIH 
in Bethesda, Maryland, making sure that an establishment of an International Scale that 
can be applied at individual centres be set in place (Hughes et al., 2003). For any local 
laboratory to adhere to the (IS) involves;             
i) Adoption of the consensus principles established by the Bethesda group 
 ii) Testing a set of reference standards to establish a laboratory specific conversion factor 
and; 
 iii) Multiply all local BCR-ABL1 values by the conversion factor to express the results 
according to the (IS). All validated laboratories worldwide use one of three reference 
laboratories based in Adelaide, London and Seattle (Hughes et al., 2003).  
Once patients are on BCR-ABL1 TKIs it is important to monitor cytogenetic and molecular  
response and development of mutations so as to identify early the subgroup of patients 
that will benefit from early intervention options (Baccarani et al., 2013). With regards to 
response to treatment, the ELN guidelines have maintained definitions of complete 
haematological response (CHR) and complete cytogenetic response (CCyR) (Baccarani 
et al., 2013). Changes were made with regards to Molecular Response, which should be 
corrected according to the International Scale (IS) as the ratio of BCR-ABL1 transcripts as 
a percentage on a log scale (Baccarani et al., 2013). (See Table 1.3).  
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Table 1.3: Definition of Response (Baccarani et al., 2013); (Louw et al., 2012). 
 
Complete haematological (CHR) 
• WBC < 10 x 109/L 
• Basophils < 5% 
• No myelocytes, promyelocytes, myeloblasts in the differential count 
• Platelet count < 450 x 109/L 
• Spleen not palpable 
 
Cytogenetic response  
• Complete (CCyR) - no Ph+ metaphases 
• Partial (PCyR) – 1-35% Ph+ metaphases 
• Major – 0-35% Ph+ metaphases (complete + partial) 
• Minor - >35% Ph+ metaphases 
 
Molecular 
• Deep molecular response (MR)- BCR-ABL1 transcript < 0.01%, 0.0032%, 
0.001% by QPCR (IS) or 4, 4.5, 5 log reduction respectively in BCR-ABL1 
mRNA from standardized baseline 
• Major molecular response (MMR)- BCR-ABL1 transcripts ≤ 0.1% or 3 log 
reduction in BCR-ABL1 mRNA from standardized baseline 
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1.6 Clinical Studies with BCR-ABL1 TKIs 
1.6.1 IRIS Trial (International Randomized Study of Interferon and STI571 Trial) 
A 5 year update of the landmark IRIS study (O’Brien et al, 2003) continued to show 
positive results for imatinib (Gleevec®). A total of 382 from the initial 553 assigned 
patients remained in front-line imatinib therapy.(Druker et al., 2006). The cumulative best 
CHR, MMR, and CCyR rate were 98%, 92%, and 87% respectively, with the estimated 
EFS (Event Free Survival) at 5 years being 83% with only 6% of patients progressing to 
advanced stage CML (O'Brien et al., 2003);  (Druker et al., 2006). The 5 year OS was 
85%, and with exclusion of non-CML deaths was 95% (O'Brien et al., 2003). Also shown 
was that depth of cytogenetic and molecular responses after 12 months and 18 months 
on imatinib therapy,  has important implications regarding survival without transformation 
(O'Brien et al., 2003); (Druker et al., 2006). 
Eight year follow-up in the phase III IRIS trial on adult patients with newly diagnosed CP-
CML. This trial reported a cumulative best CCyR of 85% and an estimated OS of 93% (in 
CML-related deaths with evidence  of low progression rates to AP and BC (Kantarjian et 
al., 2006); (Sacha, 2013). However 17% of imatinib treated patients did not achieve a 
CCyR and 10% who did achieve CCyR relapsed. An additional 8% of patients were 
intolerant of imatinib (Sacha, 2013). 
1.6.2 Dasatinib - DASISION Trial (Dasatinib versus Imatinib Study in treatment- 
Naïve CML patients) Trial 
Dasatinib (Sprycel®, Bristol-Myers Squibb), a second generation BCR-ABL TKI is 
approved as second-line therapy for patients with CML following imatinib. It is 
approximately 300 times as potent as imatinib in inhibiting unmutated BCR- ABL1 kinase 
in-vitro (Kantarjian et al., 2010).  
The DASISION Trial compared dasatinib versus imatinib in treatment naive CML patients, 
looking at efficacy and safety of dasatinib (Kantarjian et al., 2010). Dasatinib was 
administered in a dose of 100mg once daily and imatinib at 400mg once daily, in patients 
with newly diagnosed CML (Kantarjian et al., 2010). The primary objective was to 
determine whether patients who received dasatinib had a higher rate of confirmed 
complete cytogenetic response (CCyR) by 12 months after initiating treatment (Kantarjian 
et al., 2010).  30- 40% of CML patients on imatinib failed to reach CCyR by 12 months, 
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the long term outcome being less favourable with an increased risk of progression to the 
advanced stages of CML at 5 years. (Kantarjian et al., 2010). This lead to the hypothesis 
that initial therapy with more potent BCR-ABL TKIs that improve the rate of CCyR early 
after diagnosis of CML could improve the long term outcomes (Baccarani et al., 2013); 
(Hughes et al., 2006).                                                                                   
Results of this study show that 519 patients were enrolled, with 259 patients started on 
dasatinib and 260 patients started on imatinib, with a minimum follow-up of 12 months. 
(Kantarjian et al., 2010) [20] The Hasford risk score was used to stratify patients in this 
study (See Table 1.2). The rate of MMR by 12 months was also higher with dasatinib than 
with imatinib treatment (46% vs 28%).(Kantarjian et al., 2010). Also in patients in whom 
CCyR was achieved by 12 months, the rate of MMR was higher among the dasatinib 
group than the imatinib group (54% vs 39%). The rate of CCyR by 12 months in the 
dasatinib groups were 94% for low risk, 78% for intermediate risk, and 78% for high risk 
scores, when using the Hasford risk score. The corresponding imatinib CCyR by 12 
months were 76%, 72%, and 64%; for low risk, intermediate risk, and high risk scores 
respectively (Kantarjian et al., 2010). The rate of MMR by 12 months for the dasatinib 
were 56% in the low risk, 45% in the intermediate risk, and 31% in the high risk group 
(Baccarani et al., 2013); (Kantarjian et al., 2010) compared to the corresponding imatinib 
MMR by 12 months of 36%, 28%, and 16%. This therefore showed that cytogenetic and 
molecular responses were achieved quicker with dasatinib than with imatinib, with time to 
CCyR and MMR being significantly shorter with dasatinib (Baccarani et al., 2013); 
(Kantarjian et al., 2010). Rate of CML PFS at 12 months was similar at 96% for dasatinib 
and 97% for imatinib (Kantarjian et al., 2010). 
1.6.3 Nilotinib- ENESTnd Trial (Evaluating Nilotinib Efficacy and Safety in Clinical 
Trials- Newly Diagnosed Patients) Study 
Nilotinib(Tasigna®,Novartis Pharmaceuticals) is another second generation BCR-ABL 
TKI that has approximately 30 times greater potency and selectivity for BCR-ABL tyrosine 
kinase than imatinib in-vitro. (Saglio et al., 2010); (Kantarjian et al., 2006). In the phase III 
ENESTnd Trial, comparison of efficacy and safety of nilotinib (300mg or 400mg twice 
daily) with that of imatinib 400mg once daily in patients with newly diagnosed Ph+ CML in 
CP was studied (Baccarani et al., 2013); (Kantarjian et al., 2006). The end point was the 
rate of MMR (≤ 0.1% or log 3 reduction or better) at 12 months (Baccarani et al., 2013); 
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(Kantarjian et al., 2006). For this study the Sokal prognostic risk score was used to stratify 
patients accordingly, with low risk, intermediate risk, and high risk scores. (See Table 
1.2). Results were as follows, with a total of 846 patients enrolled with a new diagnosis of 
CP-CML. (Kantarjian et al., 2006). 282 patients received nilotinib 300mg twice daily 
(group A), 281 patients receiving 400mg twice daily (group B)and 283 patients received 
imatinib 400mg once daily (group C). Those that achieved MMR at 12 months were 51% 
for group A, 50% for group B, and 27% for group C (Baccarani et al., 2013); (Kantarjian et 
al., 2006). Among the patients with high Sokal scores, the rate of MMR at 12 months 
were 41% group A, 32% group B, and 17% for group C (Kantarjian et al., 2006). At the 
time of data cutoff, the BCR-ABL1 transcript level was at 0.0032% (log 4.5 reduction) or 
less on the IS in 13 % of the group A patients, 12% of the group B patients, and 4% of the 
group C patients, proving that nilotinib on either dose had a shorter  time to MMR than 
imatinib (Kantarjian et al., 2006). 
1.6.4 Bosutinib - BELA (Phase III Bosutinib Efficacy and Safety in Newly Diagnosed 
Chronic Myeloid Leukaemia) Trial 
Other second generation BCR-ABL TKIs, like bosutinib (Bosulif®, Pfizer) which is not 
registered by MCC in South Africa can also be used as second-line or third-line therapy 
for CML (Cortes et al., 2012). The BELA Trial also showed superiority of bosutinib 
compared to imatinib (Baccarani et al., 2013); (Cortes et al., 2012). This trial was a phase 
III study on adults with newly diagnosed CP-CML. This analysis was stratified using the 
Sokal risk score. A total of 502 patients were enrolled with 250 patients on bosutinib and 
252 on imatinib, at doses of 500mg once daily for bosutinib and 400mg once daily for 
imatinib respectively (Baccarani et al., 2013); (Cortes et al., 2012). It was shown in this 
study that bosutinib did not have a superior CCyR rate at 12 months when compared to 
imatinib although the MCyR at 12 months was 73% and the MMR rate at 12 months was 
higher with bosutinib than with imatinib. (Cortes et al., 2012). The influence of the Sokal 
risk score on treatment affect for CCyR and MMR at 12 months was also shown to 
demonstrate no differences (Baccarani et al., 2013); (Cortes et al., 2012).  
1.6.5 Ponatinib - EPIC (Evaluation of Ponatinib vs Imatinib in CML) Trial 
Ponatinib (Iclusig®, Ariad Pharmaceuticals) a pan-TKI has shown to be the most active of 
the tyrosine kinase inhibitors, also inhibiting the T315I BCR-ABL1 mutation which confers 
resistance to all other BCR-ABL1 TKIs, was approved by the USFDA (not SAMCC) only 
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for treatment of patients who failed therapy with other BCR-ABL TKIs (Baccarani et al., 
2013). Recently the use of ponatinib was suspended by the FDA due to the findings of 
adverse effects of arterial thromboembolic events in the EPIC Trial, which follows on the 
findings of the phase II PACE Trial. The suspension has subsequently been lifted by the 
FDA and a “Black Box Warning” re risk of thromboembolic disease (TED) added to the 
Package Insert. The EPIC trial showed that ponatinib offers improved efficacy over 
imatinib in patients with newly diagnosed CP-CML although that improvement comes at 
an expense of greater adverse events (Cortes et al., 2013). 
The trial included 307 patients, but data was only available for 306 patients (154 on 
ponatinib and 152 on imatinib), with a median follow-up of 5.1 months. Patients were 
stratified using the Sokal risk score. Doses used were ponatinib 45mg once daily and 
imatinib 400mg once daily. Overall Molecular response rates for ponatinib were uniformly 
higher compared with imatinib for all response measures and at all time points, with MMR 
at 12 months of 41% for ponatinib and 18% for imatinib. (Cortes et al., 2013). 
Furthermore at 3 months patients that had achieved MMR3 or log 3 reduction in BCR-
ABL1 transcripts was 94% for ponatinib and 68% for imatinib. (Cortes et al., 2013). When 
divided into low risk, intermediate risk, and high risk according to Sokal risk scores, the 
achievement of MMR3 was 98%, 96%, and 85% respectively for the ponatinib group of 
patients; and 76%, 69%, and 42% respectively for the imatinib group (Cortes et al., 2013). 
These results were analysed despite early termination of the trial at 5 months due to the 
serious arterial thromboembolic events, but clearly showed that ponatinib is a potent 
BCR-ABL TKI, active against native and mutated forms of BCR-ABL1, including T315I 
(Baccarani et al., 2013); (Cortes et al., 2013).  
1.7 Mutations 
1.7.1 BCR-ABL1 Kinase Domain (KD) Point Mutations 
BCR-ABL1 KD mutations contribute and cause resistance to BCR-ABL1 TKIs (Soverini et 
al., 2011). These point mutations are detectable in roughly 50% of CML patients with 
treatment failure and disease progression on BCR-ABL TKI therapy. (Baccarani et al., 
2013). More than 100 amino acid substitutions have been reported in association with 
resistance to Imatinib, while Dasatinib and Nilotinib have smaller spectra of resistant 
mutations. (Baccarani et al., 2013); (Soverini et al., 2011). 
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In general patients have many BCR-ABL1 Kinase Domain (KD) mutations that are 
sensitive in-vitro to all the BCR-ABL TKIs, and they are expressed as a half- maximal 
inhibitory concentration [IC50] (Baccarani et al., 2013). In patents in the chronic phase 
(CP) of CML, there is a relationship between the IC50 value for a specific mutation in-vitro 
and the patient’s clinical response to TKIs when harbouring the same point mutation in-
vivo. If a patient has higher IC50 levels they will have lower haematological and 
cytogenetic response rates compared to those patients harbouring mutations with lower 
IC50 values (Baccarani et al., 2013).  
BCR-ABL1 point mutations in CML are important for optimal treatment. There are 
different kinds of KD point mutations of which two will be discussed here. The P-loop 
region KD mutations on exon 4 are insensitive to imatinib and nilotinib. Other KD 
mutations on exon 6 are insensitive to imatinib, dasatinib, and in some cases bosutinib. 
(Gorre et al., 2001); (Soverini et al., 2011). The T315I mutation results in an amino acid 
substitution at position 315 in the BCR-ABL1 from threonine to an isoleucine. The T315I 
mutation is the most implicated BCR-ABL1 point mutation described for development of 
pan-TKI; imatinib, dasatinib, nilotinib, and bosutinib resistance. The only drug that has 
retained sensitivity to T315I mutation is Ponatinib (Gorre et al., 2001). 
Imatinib which was first approved by the FDA in 2001 and by the MCC in 2002 with an 
indication for use in diagnosed CML patients after interferon-α treatment failure. Imatinib 
has reduced sensitivity to almost all the common mutations, both P-loop (exon 4) and KD 
(exon 6) mutations. The list of mutations responsible for imatinib resistance include T315I, 
T315A, G250E, Y253H, E255K/V, C276G, M351T, L387M, F317L/C/V, F359C/I/V 
(Soverini et al., 2011).  
Dasatinib a second generation BCR-ABL1 TKI developed for patients proven to be 
imatinib resistant or have had failure of disease response to prior therapy, in most 
instances imatinib.(Soverini et al., 2007). Dasatinib has decreased sensitivity to the KD 
(exon 6) mutations namely; T315I/A, F317/L/C/V/I. Dasatinib also shows decreased 
sensitivity to V299L mutation, which is in a SH3 (SRC- homology 3) contact region 
mutation of the KD on exon 5 (Baccarani et al., 2013); (Soverini et al., 2007). 
Nilotinib another second generation BCR-ABL TKI developed for imatinib intolerance, 
resistance or treatment failure. Its range of resistant mutations besides the T315I, are 
18 
 
divided between P-loop mutations; Y153H, E255K/V, and the KD mutations are F359C, 
F359I, and F359V. If any of the above mutations are expressed on a mutational analysis, 
then the recommendation is to rather use dasatinib instead of nilotinib (Soverini et al., 
2011).  
Therefore,  the use of BCR-ABL1 P-loop and KD mutational analysis plays a pivotal role 
in the decision making aimed at tailoring the best therapeutic profile for each patient 
(Soverini et al., 2011). There is however, a need to clarify on when to do the mutational 
analysis. This is because  some data has shown that in some patients more especially 
those presenting in advanced stages of CML, may already have preexisting genetic 
instability and harbour some in-vivo mutations before initiation of a BCR-ABL TKI therapy 
(Soverini et al., 2011).  
This raises the question of the need to do mutational studies prior to initiation of BCR-ABL 
TKI therapy in advanced phase CML patients (Soverini et al., 2011). 
As it stands, there is no evidence for testing for point mutations in CP- CML patients prior 
to starting a BCR-ABL1 TKI, but there possibly could be a role especially in those patients 
presenting in advanced phases of CML (Soverini et al., 2011).    
Therefore there should be appropriate labeling of resistance, namely primary and 
acquired resistance (Soverini et al., 2011).  
It then seems that the ideal time for performing mutational analysis is on those patients 
showing treatment failure and when there is suboptimal response to BCR-ABL TKI 
therapy. There could also be a role as mentioned above in those patients presenting in 
advanced phases of CML (e.g. AP-CML, BC-CML) (Soverini et al., 2011).  
1.8 Stem Cell Transplants 
1.8.1 Allogeneic Haematopoietic Stem Cell Transplant 
Allogeneic haematopoietic stem cell transplantation (AlloSCT) is no longer considered as 
standard first-line treatment or included in any guideline for CML, but it remains the only 
potentially curative treatment option which can render patients durably molecularly 
negative (Louw et al., 2012). It is however associated with a high incidence of procedure-
related morbidity and mortality especially in the elderly (Baccarani et al., 2013). However 
there are a few studies that incorporate this treatment modality.(Grigg and Hughes, 
2006). 
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The European Group for Blood and Marrow Transplantation (EBMT) risk score provides a 
simple tool to assess the outcome and risk of stem cell transplantation (AlloSCT) 
(Gratwohl, 2012). CML is the foundation from which AlloSCT was established as a 
treatment modality in other haematological malignancies (Forrest et al., 2009). Five 
factors are assessed with the EBMT score to give a clue on transplantation outcome 
namely; age, disease stage, time interval (from diagnosis to AlloSCT), donor type, and 
donor recipient tissue type. Each risk factor is individually important but all add to the 
overall cumulative risk (Gratwohl, 2012); (Grigg and Hughes, 2006). (Gupta and Khattry, 
2014). With this tool, reasonable accuracy can be applied as to what the outcome after 
AlloSCT will be, with transplant related mortality (TRM) increasing in a stepwise pattern 
as the risk score increases, and survival decreasing correspondingly (Gratwohl, 2012).  
Initial data comes from comparing baseline therapy between AlloSCT and systemic 
treatment with Inteferon-α and hydroxyurea (Gratwohl, 2012). The decision making in this 
regard involves a risk benefit assessment, with allotransplantation having a known high 
risk of early mortality, notwithstanding the prospect of a cure (Grigg and Hughes, 2006). 
On the other hand systemic chemotherapy renders minimal early morbidity and mortality. 
This EBMT risk score was used in CML patients who were treated with either of two pre-
transplant modalities, myeloablative or reduced intensity conditioning followed by either 
transplantation with bone marrow stem cells or peripheral blood stem cells (Gratwohl, 
2012); (Grigg and Hughes, 2006). This score still holds true today in the era of BCR-ABL1 
TKI’s.  
In the IRIS Trial and follow-up studies imatinib was shown to be superior in the short and 
medium term when looking at PFS and OS, therefore replacing earlier therapies, more 
especially AlloSCT as initial treatment of choice in CP-CML (Grigg and Hughes, 2006).  
AlloSCT is no longer the preferred first-line therapy but possibly third-line after giving 
other more potent second generation BCR-ABL TKIs. To date in all review studies, 
disease stage and timing of treatment have shown to play a critical role in deciding which 
first-line therapy is more suitable (imatinib vs AlloSCT). CP1-CML has been suggested as 
a possible suitable time to make the decision of transplantation over a BCR-ABL1 TKI, 
although not currently standard use or part of any guideline. Factors that can assist in this 
decision making are the prognostic Sokal score and the EBMT score (Grigg and Hughes, 
2006). There is a suggestion that individuals with high Sokal risk scores and low EBMT 
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scores have unsatisfactory CCyR and MMR while on imatinib at 12 months of follow-up, 
49% and 18% respectively (Grigg and Hughes, 2006). Therefore these are the patients 
that may benefit from a decision to treat with AlloSCT. Arguments have however been 
raised to rather increase imatinib dose or switching to a second generation BCR-ABL TKI 
instead in cases of poor response, improving CCyR and MMR thus achieving longer PFS 
and OS (Grigg and Hughes, 2006).  
The recommendation therefore is  that imatinib and possibly nilotinib or dasatinib be the 
treatment of choice for first-line therapy in newly diagnosed CML patients (Baccarani et 
al., 2013); (Grigg and Hughes, 2006). AlloSCT can be reserved for patients who fail to 
respond to TKIs or have disease progression on BCR-ABL TKIs, or in patients developing 
resistant mutations (Baccarani et al., 2013); (Gratwohl, 2012); (Grigg and Hughes, 2006).  
Almost 50% of patients who are started on BCR-ABL TKI therapy for CML will either 
develop treatment failure to one or all the BCR-ABL1 TKIs or have disease progression 
depending on the BCR-ABL1 kinase point mutation formed. As mentioned, more than 100 
mutations have been reported in association with imatinib resistance, most of them can 
be overcome by the use of dasatinib or nilotinib which have a narrower spectrum of 
resistant mutations (Baccarani et al., 2013).    
1.9 HIV and CML 
1.9.1 CML and Human Immunodeficiency virus (HIV) 
In a review of a paper by Patel et al, the finding of CML and HIV was coincidental with no 
link between the two pathologies. (Patel et al., 2012). Indeed there have been very few 
cases reported of the HIV and CML occurring in the same patient. (Schlaberg et al., 
2008). Patel and his colleagues also pointed out in their paper that HIV infected patients 
tend to present with a more aggressive clinical picture instead of presenting in the chronic 
phase. (Patel et al., 2012). Their cohort of HIV infected patients at Chris Hani 
Baragwanath Academic Hospital (CHBAH) in Soweto, Johannesburg consisted of 18 out 
of the 240 patients known and treated for CML. (Patel et al., 2012). They also looked at 
was the concomitant use of highly active antiretroviral therapy (HAART) and BCR-ABL1 
TKI therapy. Their view was that there were no significant drug interactions with a good 
outcome reported with regards to controlling both CML and HIV. (Patel et al., 2012). They 
also looked at the concomitant use of highly active antiretroviral therapy (HAART) and 
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BCR-ABL TKI therapy. Their view was that there were no significant drug interactions with 
a good outcome reported with regards to controlling both CML and HIV. (Patel et al., 
2012). In addition the long-term survival achieved by these patients was similar to HIV-
negative patients. Tolerability to BCR-ABL1 TKIs was equally good and similar to non-
infected patients. (Patel et al., 2012). Of notice, the only adverse effect reported in this 
cohort was a tendency of the CD4 count to drop without the viral load being affected. 
(Patel et al., 2012). 
 
 
In another paper by Schlaberg and colleagues, it was also shown that there was no real 
association of concurrent HIV and CML and that the only reasonable explanation of CML 
occurring in HIV infected patients or visa- versa was due to the long term survival of HIV 
patients on HAART (Schlaberg et al., 2008). Only 6 patients had been found to have 
these two pathologies concurrently, with 3 of them formally reported. (Schlaberg et al., 
2008). These three patients were put onto imatinib and HAART, with the HAART regimen 
not specified. (Schlaberg et al., 2008).  
 
They reported that therapy was generally well tolerated with cytogenetic response 
achieved in all 3 patients, with complete cytogenetic response achieved in 2 out of 3 of 
the patients after a follow up of 3 to 69 months. (Schlaberg et al., 2008).  
In this paper, in contrast to the one by Patel and colleagues, it was mentioned that the 
viral loads and CD4 counts were stable during therapy and that concurrent HAART and 
imatinib resulted in appropriate control of both HIV infection and CML. Therefore there 
were no major drug interactions reported. (Schlaberg et al., 2008).  
In our South African context, many of our HIV infected patients are at increased risk of 
opportunistic infections like tuberculosis (TB). (Schlaberg et al., 2008). Drug interactions 
are well documented for TB drugs especially rifampicin, which has a bactericidal 
antibacterial role in the therapy of TB, and forms the framework of TB therapy. (Schlaberg 
et al., 2008);  (Haouala et al., 2010). Rifampicin induces CYP3A4, therefore causing 
decreased exposure of all 3 BCR-ABL TKI’s available in our setting for treatment of CML 
namely; imatinib, nilotinib, and dasatinib (Schlaberg et al., 2008). This the means that 
while on TB therapy, CML patients on BCR-ABL TKI’s will require a dosage increase of 
the BCR-ABL TKI therapy till completion of TB treatment (Schlaberg et al., 2008).       
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Chapter 2    
Patients and methods 
2.1 Aim and Objectives 
To review all patients treated for CML at the CMJAH Medical Oncology unit from 2002 to 
2015 to acertain: 
1.  Clinical presentation and stage of disease at time of diagnosis 
2.  Response to initial BCR-ABL1 TKI therapy 
3.  Disease progression and reason for change to second-line or third-line BCR-
ABL1 TKI therapy 
4.  Adverse events on BCR-ABL1 TKI therapy 
5.  Development of BCR-ABL1 mutations 
2.2 Methodology 
2.2.1 Study type 
This is a retrospective study involving a cohort of 101 patients with CML treated at the 
Medical Oncology Unit at CMJAH from 2002 to 2015.  
Permission was obtained through the CEO at the Charlotte Maxeke Johannesburg 
Academic Hospital, Ms G Bogosi and through the Head of Medical Oncology at University 
of Witwatersrand Faculty of Health Sciences. Ethics approval was obtained from the 
University of Witwatersrand Human Research Ethics Committee (Medical) (Ethics 
Number: M140255) on the 03/03/2014.  
2.2.2 Study population 
This study looks at patients treated for CML with BCR-ABL1 TKIs and to see how the 
management of CML has advanced since the advent of BCR-ABL1 TKI’s compared to the 
older treatment modalities, namely interferon-α +/- cytarabine, hydroxyurea and 
allogeneic stem cell transplantation.  
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2.2.2.1 Inclusion criteria  
Patients with BCR-ABL1 positive CML 
 
2.2.2.2 Exclusion criteria  
BCR-ABL1 negative Patients 
 
2.2.3 Patient clinical and molecular evaluation 
Response to BCR-ABL TKIs was assessed clinically and by evaluating molecular 
response using reverse transcriptase real-time quantitative PCR (RQ-PCR) while on 
BCR-ABL TKI therapy, RQ-PCR values were referenced from the ELN guidelines. (See 
Table 1.3) RQ-PCR was in most instances done at 3 to 6 monthly intervals with regards 
to monitoring. A shortfall arose as some patients did not have complete monitoring of 
disease response to BCR-ABL1 TKI therapy recorded in the files studied. 
 
2.2.4 Data collection and analysis 
The initial data was collected using a data collection sheet that comprised several 
variables. The variables were tabulated allowing for correct insertion of information 
required for analysis.  
The headings were as follows; age gender, family history, clinical features in the form of 
symptoms and signs, haematological features, date of death if death occurred, and 
adverse event profile. A modification was then made with molecular response by RQ-
PCR being manually added to the data collection sheet. 
Response to treatment in CML is assessed by evaluating molecular response, using 
standardized real time quantitative polymerase chain reaction (RQ-PCR), as well as 
cytogenetics although the first corrective measure when treating CML however is to 
achieve a complete haematological response. 
As described above, a data collection sheet with variables that had to be answered was 
used to look at clinical features at diagnosis as well as at the effectiveness of BCR-ABL1 
TKIs in the management of CP-CML. Secondary tasks were to see if patients developed 
mutations to BCR-ABL TKI therapy followed by evaluating the overall survival. The 
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following results were found to be true at this particular oncology unit with regards to the 
above hypotheses together with other variables such as demographics and presentation 
of CML.  
2.2.4.1 Sokal score 
The Sokal score was also one of the variables on the data collection sheet. This score is 
of prognostic significance as it assists with predicting the possible response and outcome 
of a particular individual to therapy prior to starting treatment. For this study only the 
Sokal score was used as a a prognostic index.  
For the Sokal prognostic score to be calculated, certain variables had to be obtained. This 
was at times difficult as not all patient files had hard copies of the initial results or proper 
documentation of such results.  
The Sokal score is calculated by the following formula: 
“Exp 0.016 x (age- 43.3) + 0.0345 x (spleen- 7.51) + 0.188 x [(platelet 
count / 700) – 0.563] + 0.0887 x (blast cells – 2.10)” [1];[23] 
However for this study, a computer generated App was used. The final calculation was 
then placed accordingly on a risk definition scale; with low risk Sokal score being < 0.8, 
intermediate risk 0.8– 1.2, and high risk >1.2.  
A descriptive analysis format with tables was the most used format of analysis   of age at 
presentation, family history of CML, whether the presentation was incidental or not, 
treatment response, mutational analysis and patient outcome. Graphs were used for 
presentation with symptoms and signs plotted respectively while pie charts were used to 
show the role of gender in the prevalence of CML, and disease stage at presentation. 
(See Figure 3.1). 
2.3 Sample Size  
The sample size includes 101 patients treated for CML with TKIs at CMJAH from 2002 to 
2015. 
. 
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Chapter 3 
 Results 
 
Age and Gender:  
 
101 patients with CML were treated at the CMJAH Medical Oncology unit between 2002 
and 2015 of whom 48% (number) were male and 52% (number) were female, with a 
median age of 40 years (Range) 
 
Table 3.1: Age at Presentation 
 
N 
 Median age 
Percentiles 
25 50 75 
101 40.00 27.00 40.00 53.00 
 
 
 
 
Figure 3.1: Gender 
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Presentation 
 
CML Phase at presentation 
 
89 (88%) of the patients presented with CP-CML with 1% in accelerated Phase and 11% 
phase unknown. 
 
 
Figure 3.2: Disease phase at initial presentation  
 
Clinical Presentation 
92 (91%) of patients reported clinical symptoms and/or had documented signs on initial 
presentation while 9% presented incidentally. There was no familial link in our CML 
patients. 
Table 3.2: Family History and Clinical Presentation 
 Frequency Percent 
Family History 0 
 
0% 
 
No Family History 101 100% 
Incidental finding 9 9% 
Clinical signs and symptoms 92 91% 
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Symptoms and signs 
Common symptoms at diagnosis were early satiety, fatigue and weight loss, and the 
commonest clinical sign found was splenomegaly.  
 
 
 
Figure 3.3: Clinical Symptoms 
 
 
 
 
Figure 3.4: Clinical Signs 
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Prior therapy 
 
Patients who were started therapy before the introduction of BCR-ABL TKI therapy, were 
treated with interferon-α therapy with or without cytarabine. 15 (15%) of patients in this 
cohort were initially on interferon-α while 85% had no prior exposure to interferon-α and 
started on imatinib as the 1st line therapy. 86 (85%) patients were diagnosed during or 
after the year 2002 when BCR-ABL TKI therapy started being available at the CMJAH 
Medical Oncology 
 
Table 3.3: Prior Interferon-α Therapy 
  Frequency Percent 
Interferon alpha Yes 15 15% No 86 85% 
 
 
Outcome 
First line BCR-ABL1 TKI: 
Of the 15 patients post interferon-α only 8 (53%) responded to imatinib, with 7 of these 
having a documented mean response time of 65.30 months. Seven (47%) patients in this 
cross-over group didn’t respond to imatinib. 
Of a total of 86 treatment-naïve patients only 85 (98.8%) were started on first line 
imatinib, with one (1.2%) patient never starting on BCR-ABL1 TKI therapy. 35% (30) of 
the 85 patients showed molecular response to first line imatinib therapy in a mean 
response time of 26.36 months, which was documented in 28 patients only. 64% of 
patients did not respond to first line imatinib therapy. When looking at both arms totaling 
100 patients who received imatinib either as a cross-over from interferon based therapy 
or as first line therapy, 38% (n= 38) of these patients responded to first line imatinib at a 
mean time of 35.75 months. 
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Table 3.4: Prior interferon-α versus 1st line BCR-ABL TKIs. 
First BCR-
ABL TKI 
 Prior Interferon (n=15) Treatment Naïve (n=86) Total (n=101) 
Yes 100.0% 98.8% 99.1% 
No 0.0% 1.2% 0.9% 
TKI MMol 
Response 
(MMR) 
 n=15 n=85 n=100 
Yes 53% (8) 35% (30) 38% (38) 
No 47% (7) 64% (54) 60% (61) 
Unknown 0% (0) 1% (1) 1% (1) 
Mean 
Response 
Time(Months) 
 n=7 n=28 n=100 
 
65.30 months 
 (SD =14.944) 
 
26.36 months 
(SD =19.320) 
 
35.75 months 
(SD =25.727) 
 
  
Second line BCR-ABL1 TKI: 
Seven patients from the initial interferon cohort not responding to imatinib after cross-over  
were then switched to a second line BCR-ABL TKI either nilotinib or dasatinib. Five 
patients went on to respond to 2nd line BCR-ABL TKI therapy but only 3 had a 
documented time of response with a mean of 28.97 months. 
The interferon naïve cohort had a total of 54 patients who responded inadequately to first 
line imatinib. 35 (64.8%) of the 54 patients were switched to second line BCR-ABL TKI 
therapy.  12 out of 35 (34%) of these patients were shown to respond to 2nd line BCR-
ABL TKI within mean a time of 8.65 months while 23 of the 35 (66%) patients never 
responded to second line BCR-ABL TKI therapy. One patient had inadequate 
documentation of response in both arms.  
Overall, a total of 40 patients (of the 61 imatinib failures) were switched to second line 
BCR-ABL TKI therapy. 17 of the 40 (43%) responded to second line BCR-ABL TKI 
therapy. Only 13 patients of the 17 (76%) had a documented time for response with a 
mean time of 13.34 months while 23 patients (57%) responded inadequately to 2nd line 
BCR-ABL TKIs and one patient having inadequate documentation of response. 
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Table 3.5: 2nd line BCR-ABL TKI: Reasons for Switching and Molecular Response 
  Prior Interferon (n=7) 
Interferon-Naive 
(n=54) Total (n=61) 
Second BCR-
ABL TKI 
Yes 71.4% (5) 64.8% (35) 66.0% (40) 
No 28.6% 35.2% 34.0% 
Reason for 
switch  
 n=5 n=35 n=40 
Disease Progression 100% (5) 89% (31) 90% (36) 
Intolerance or A/E to 
imatninb 0% (0) 11% (4) 10% (4) 
TKI MMol 
Response 
(MMR) 
 n=5 n=35 n=40 
Yes 100% (5) 34% (12) 43% (17) 
No 0% (0) 63% (22) 55% (22) 
Unknown 0% (0) 3% (1) 3% (1) 
Mean 
Response 
Time 
(Months) 
 n=3 n=10 n=13 
 
28.97 months 
 (SD =16.928)  
 
8.65 months 
(SD =6.799) 
 
13.339 months 
(SD =12.721) 
 
 
Third line BCR-ABL1 TKI: 
Of the 22 patients who failed a second line BCR-ABL TKI, only 6 (27.3%) went on to third 
line BCR-ABL TKI therapy, either nilotinib or dasatinib leaving the remainder of the 
patients 16 (72.7%) not switching to any 3rd line therapy. Of the 6 patients who went on to 
3rd line therapy, only one (16.7%) responded to therapy at a mean time of 18.3 months, 
while 5 patients did not respond to therapy.  
 
Table 3.6: 3rd line BCR-ABL TKI: Reasons for Switching and Molecular Response 
  Did not Start on Interferon (n=22) 
Third BCR-ABL TKI 
Yes 27.3% (6) 
No 72.7% (16) 
Reason 
 n=6 
Disease Progression 66.7% (4) 
Intolerance to TKI or side effects 33.3% (2) 
TKI MMol 
Response 
 n=6 
Yes 16.7% (1) 
No 83.3% (5) 
Response Time 
(Months) 
 n=1 
 18.30 months 
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Mutational analysis 
BCR-ABL1 Mutational Analysis was performed on only 3 (3%) of the patients who either 
lost their MMR or didn’t respond at all (never reached MMR) to BCR-ABL TKI therapy. 
Two patients had a pan-resistant T315I mutation, and were therefore resistant to imatinib, 
dasatinib, and nilotinib while one patient had a p-loop Y253H mutation, showing 
resistance to imatinib and to some extent nilotinib but not to dasatinib. 
 
Table 3.7: Mutations analysed 
  Frequency Percent 
Mutations 
Yes 3 3% 
No 98 97% 
 
 
Follow up status 
64% of patients are still attending the Medical Oncology clinic, while 36% have been lost 
to follow up. 
 
Table 3.8:  Follow-up Status 
  Frequency Percent 
Status 
Lost to Follow Up 36 36% 
On Follow Up 64 64% 
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Adverse Events 
The adverse effects most experienced by the patients on BCR-ABL1 TKI therapy were 
cytopenias (39%), muscle cramps (25%), superficial oedema (9%), with rash, nausea and 
vomiting occurring less frequently. Of the 101 patients, only sixty three (63) had 
documented A/Es (in the above bar graph). Cytopenias were seen mainly in those 
patients on imatinib or dasatinib therapy especially neutropenia and/or thrombocytopenia, 
with a few patients had anaemia. Neutropenias or thrombocytopenias rarely were grade 
3/4 (9%), although the 9 patients who had grade 3/4 cytopenias had to be switched to 
another BCR-ABL TKI.  
 
 
Figure3.5:  Adverse Effects of BCR-ABL1 TKIs 
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Chapter 4  
Discussion 
CML has historically been shown to be potentially cured by performing an AlloSCT, with 
the best timing being in the CP1-CML. However since the advent of BCR-ABL1 TKIs, 
AlloSCT has been superseded as 1st line treatment of choice for newly diagnosed CP-
CML. BCR-ABL TKIs have a favourable toxicity profile with deep molecular responses 
and prolonged PFS. This study initially looked at a cohort of 150 patients receiving BCR-
ABL TKIs at the CMJAH Oncology unit, however only 101 patient files with CML were 
analysed as there were files of patients receiving imatinib for diagnoses other than CML, 
including gastrointestinal stromal tumours (GISTs). 
 
Evidence shows that there is a male preponderance as compared to female patients that 
present with CML worldwide (Louw et al., 2012), however in this study there were slightly 
more females presenting with CML than males i.e. 53 (52%) females and 48 (48%) 
males. The median age of patients with CML in this cohort was 40 years, with the 
youngest patient being 16 years old and the most elderly being 80 years of age. In the 
literature review the median age was 50 years (Louw et al., 2012); (Walz et al., 2008), 
suggesting the possibility of a younger age of presentation in low middles income 
countries (LMICs) including South Africa.  
Another interesting finding is that only 9 percent of patients presented incidentally with a 
raised WBC, with the remaining patients having documentation of clinical symptom/s or 
sign/s at presentation. This also varied from the literature review where most patients 
diagnosed with CML were said to present incidentally with a finding in the blood of a high 
WBC count without any presenting clinical features (Louw et al., 2012).  
 
The most common symptoms reported was early satiety (24%), fatigue (23%), and weight 
loss (18%), demonstrated in the bar graph in the results section (Figures 3.3 and 3.4). 
Clinically the most common clinical sign was splenomegaly, with 71% of patients having 
this sign at presentation, which is not too varied from the evidence shown in the literature 
review (Louw et al., 2012). The size of the spleen was not uniformly recorded across the 
board although for the purpose of this study spleen size was required due to its 
importance as a variable in the calculation of the prognostic Sokal score (Sokal et al., 
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1984). Another reason spleen size is important is to monitor disease response to BCR-
ABL TKI therapy. However this was not feasible for this study as there was no continuity 
in objective documentation of spleen size at every doctor’s visit in the files studied. 
 
When looking at CML phase at presentation, the literature review and the study results 
were similar with most of the patients (88%) presenting in the CP-CML (Walz et al., 
2008); (O'Brien et al., 2003). Only one patient presented in the accelerated phase while 
none of the patients presented de novo in the blast phase (BP). In 11% of patients the 
phase was not known at presentation, due to paucity in documentation in the patient files.  
 
Some clinic patients came from an a STI-571 Expanded Access Programme (EAP), 
which was conducted before MCC registration of imatinib (Gleevec®) and the 
commencement of the GIPAP at the Medical Oncology Clinic  in 2002/2003. Hence these 
patients’ original clinical data was not in the clinic files and was not available for review. 
Only 55% of the patients had all the variables available to calculate the Sokal prognostic 
score. This score is of significance as it makes for an important prognostic tool for newly 
diagnosed CML patients independent of response to BCR-ABL1 TKI therapy and is also 
useful in the early recognition of those patients who are likely to achieve favourable 
outcomes of OS and PFS. Of these patients; 20% had a low risk, 41.8% a moderate risk 
and 38.2% a high risk Sokal score.  
 
Treatment response was analysed for 100 patients in total as one patient who presented 
to the clinic with a diagnosis of CML had a head injury resulting in an intracranial bleed. It 
was then decided by the attending physician at the time of presentation that this particular 
individual wasn’t a candidate to receive BCR-ABL1 TKIs. 
A molecular response was assessed as achieving at least MMR 3 (> 3 Log Reduction) in 
response to imatinib. Of the patients on the interferon-α group that crossed over to 
imatinib, 53% responded to their imatinib at a mean time of 65 months. In the 1st line 
imatinib cohort (interferon naive) 35% of the 85 patients responded to first line BCR-ABL 
TKI therapy at a mean duration of 26 months, while of the overall 100 patients, 38% 
responded to imatinib at a mean duration of 36 months. 
 
35 
 
The prior interferon group responded at a mean time of 28 months to second line BCR-
ABL TKI therapy (nilotinib or dasatinib) compared to a mean time of 65 months it took for 
response to first line imatinib to occur, while the interferon naïve cohort took a mean time 
of 9 months to respond to second line BCR-ABL1 TKI therapy in comparison to a mean 
time of 26 months while on first line (imatinib) therapy. 
Of the 6 patients switched to third line therapy (again either dasatinib or nilotinib) because 
of treatment failure or intolerance of second line BCR-ABL1 TKI therapy, only one patient 
responded at a mean time of 18 months.  
 
Results reported in this study show that, as in most trials mentioned in the literature 
review comparing earlier treatment modalities and the newer BCR-ABL TKIs, there is a 
definite prolonged progression free survival and overall survival benefit and less 
transformation to advanced stage CML (Louw et al., 2012); (O'Brien et al., 2003). Those 
not responding to first line BCR-ABL1 TKI therapy or progressing to advanced stages of 
CML have an encouraging outlook as they can be switched to a second generation BCR-
ABL1 TKI and achieve good disease response, including deep molecular responses. Also 
evident is the superiority of the second generation BCR-ABL1 TKIs in terms of shorter 
time to response achieved with dasatinib and/or nilotinib than with imatinib. Second 
generation BCR-ABL1 TKIs appear to be more efficacious, and have a comparatively 
better CML PFS than imatinib although in terms of OS there isn’t yet enough data to 
compare outcomes. 
 
Of the total 101 patients, only 3 (3%) were documented to have developed resistant 
mutations to the TKIs. Two of these patients had a pan-resistant T315I mutation, making 
them resistant to all three available TKIs in our setting possibly requiring the pan-TKI 
ponatinib which is not yet available in South Africa. One patient had a p-loop Y253H 
mutation which results in complete resistance to imatinib and partial resistance to nilotinib 
but sensitivity to dasatinib. 
 
AlloSCT still remains the only treatment modality that can possibly cure CML patients but 
its role in therapy has been largely replaced by highly efficacious BCR-ABL1 TKI therapy. 
AlloSCT should therefore probably be reserved for patients who develop mutations, those 
who do not tolerate BCR-ABL TKIs and those who have disease progression or develop 
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accelerated or blast crises on available BCR-ABL TKI therapy although these patients 
need to be in a second CP (CP-2) CML to receive an allotransplant.  
 
36 (36%) of our patients were lost to follow up, while 64 (64%) are still attending the 
Medical Oncology clinic to date with the majority having achieved a favourable response 
to 1st or 2nd line BCR-ABL1 TKIs of a MMR3 (>3 Log Reduction) or more.  They also have 
achieved a prolonged OS and PFS and still remain on BCR-ABL1 TKI therapy.  
 
The adverse effects most frequently reported in this cohort of patients on BCR-ABL1 TKI 
therapy were cytopenias, muscle cramps and superficial oedema. Very few patients 
experienced grade 3/4 A/Es including neutropenia and thrombocytopenia which were due 
mainly to dasatinib and imatinib, and required a switch to nilotinib which proved to be 
more tolerable with regards to their cytopenia.   
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Chapter 5  
Conclusion 
Patients treated at the CMJAH Medical Oncology Unit with BCR-ABL TKIs for CML 
generally show a moderate molecular response to both the first generation BCR-ABL1 
TKI imatinib and to the second generation BCR-ABL TKIs, dasatinib and nilotinib, with at 
least an MMR3 (>3 Log Reduction) being achieved in 38% of first line and 43% of second 
line cohort of patients. However there is evidence to show that a quicker response time 
was achieved on a 2nd line BCR-ABL TKI (either dasatinib or nilotinib) than with 1st line 
imatinib therapy.  
Where comparing time to molecular response, patients who received prior interferon, 
responded to a first line BCR-ABL1 TKI with a mean time to MMR of 65 months, while 
those who received a 2nd line BCR-ABL TKI responded with a mean time to MMR of 28 
months. Also the interferon naïve group took a mean of 26 months to respond to 1st line 
imatinib compared to a mean of 9 months to respond to a 2nd line BCR-ABL1 TKI.  
With both the interferon and imatinib group combined, the joint time to major molecular 
response to 2nd line BCR-ABL1 TKI therapy was 13 months compared to 35 months with 
first line imatinib. 
The adverse event profile observed was mainly haematological with cytopenias especially 
neutropenia and/or thrombocytopenia being frequently observed. The culprit drug/s were 
more often dasatinib or imatinib, with a benefit achieved by switching to nilotinib.  
At the time of data collection only three patients were found to have developed BCR-
ABL1 mutations, two with a pan-resistant T315I mutation and one with a p-loop Y253H 
mutation. Patients who develop T315I mutations have no other treatment options as we 
do not have ponatinib available. These patients will eventually progress to advanced 
phases of CML and demise. Also AlloSCT is not possible in the event of progression to 
blast crisis as CP-2 CML is impossible to achieve without the necessary therapy.   
However for the patients whose molecular responses have been favourable on BCR-
ABL1 TKI therapy, whether 1st or 2nd line, prolonged OS and PFS have been achieved, 
with CP-1 of CML maintained without the need for salvage therapy including allogeneic 
stem cell transplantation. Indeed 64 (64%) patients remain on ongoing follow-up in 
chronic phase CML in our Medical Oncology clinic. 
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